Malaria DNA vaccine - EntreMed
Latest Information Update: 21 Dec 2004
Price :
$50 *
At a glance
- Originator National Institutes of Health (USA)
- Developer EntreMed
- Class Antimalarials; DNA vaccines; Gene therapies; Parasitic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Malaria
Most Recent Events
- 21 Dec 2004 Discontinued - Preclinical for Malaria in Panama (unspecified route)
- 21 Dec 2004 Discontinued - Preclinical for Malaria in Peru (unspecified route)
- 14 Nov 2002 Suspended - Preclinical for Malaria in Panama (unspecified route)